UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 64,690 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 15.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 472,964 shares of the company's stock after acquiring an additional 64,690 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.38% of Vaxcyte worth $38,717,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. Nisa Investment Advisors LLC grew its stake in shares of Vaxcyte by 21.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,684 shares of the company's stock valued at $220,000 after buying an additional 475 shares during the period. Avior Wealth Management LLC raised its stake in Vaxcyte by 21.1% during the 4th quarter. Avior Wealth Management LLC now owns 6,456 shares of the company's stock worth $528,000 after acquiring an additional 1,124 shares in the last quarter. Blue Trust Inc. raised its stake in Vaxcyte by 125.1% during the 4th quarter. Blue Trust Inc. now owns 835 shares of the company's stock worth $68,000 after acquiring an additional 464 shares in the last quarter. KBC Group NV increased its stake in Vaxcyte by 78.0% in the fourth quarter. KBC Group NV now owns 4,775 shares of the company's stock valued at $391,000 after purchasing an additional 2,092 shares during the period. Finally, Chicago Partners Investment Group LLC increased its stake in shares of Vaxcyte by 9.2% during the fourth quarter. Chicago Partners Investment Group LLC now owns 5,431 shares of the company's stock worth $440,000 after acquiring an additional 458 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PCVX. The Goldman Sachs Group reduced their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Needham & Company LLC reissued a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a report on Tuesday, April 8th. Bank of America reduced their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Cantor Fitzgerald began coverage on shares of Vaxcyte in a research report on Tuesday, April 22nd. They issued an "overweight" rating on the stock. Finally, Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $136.50.

Vaxcyte Stock Performance

PCVX stock traded down $0.46 during mid-day trading on Friday, hitting $32.34. 512,582 shares of the company were exchanged, compared to its average volume of 1,399,861. The firm has a market cap of $4.17 billion, a P/E ratio of -7.05 and a beta of 1.27. The firm's 50 day simple moving average is $35.12 and its 200 day simple moving average is $67.44. Vaxcyte, Inc. has a 1-year low of $27.66 and a 1-year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the company earned ($0.85) EPS. On average, equities research analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares of the company's stock, valued at approximately $11,351,794.37. The trade was a 4.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 3.10% of the company's stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.